Janssen terminated a seven-year-old vaccine collaboration with Bavarian Nordic. The two companies partnered in 2015 to develop potential vaccines against the hepatitis B virus and human papillomaviruses.
Silverback Therapeutics is halting the company’s clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave Silverback with more cash reserves.
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
Spring Bank Pharmaceuticals, based in Hopkinton, Massachusetts, is discontinuing development of inarigivir soproxil for chronic hepatitis B virus (HBV).
According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.
Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
GlaxoSmithKline exercised an option to license Ionis Pharmaceuticals’ antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.
A collaboration and license deal was inked with Gilead Sciences Inc. to develop and market a long-acting injectable HIV therapy using Durect Corp.’s SABER technology.
VBI Vaccines Inc. said a late-stage study testing the company’s hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met the main goals.
Gilead Sciences Inc. is acquiring the global rights to develop and commercialize novel small molecules against two targets from South Korea-based Yuhan Corporation.